BioLife Solutions Reports Strong Q4 & FY25 Results, Guides for 2026 GAAP Profitability

summarizeSummary

BioLife Solutions announced robust fourth quarter and full year 2025 financial results, exceeding revenue expectations and projecting a return to full-year GAAP profitability in 2026.

check_boxKey Events

• Strong Q4 & FY25 Revenue Growth

  Reported Q4 2025 revenue of $24.8 million, an increase of 20% year-over-year, and full year 2025 revenue of $96.2 million, up 29% year-over-year.

• Return to Q4 GAAP Profitability

  Achieved GAAP net income of $2.1 million, or $0.04 per share, for Q4 2025, reversing a net loss of $1.2 million in Q4 2024.

• Positive 2026 Financial Guidance

  Introduced 2026 revenue guidance of $112.5 million to $115.0 million, representing 17% to 20% growth, and expects full-year GAAP profitability.

• Adjusted EBITDA Expansion

  Reported Q4 2025 Adjusted EBITDA of $6.9 million (28% of revenue) and FY 2025 Adjusted EBITDA of $25.0 million (26% of revenue), with continued expansion expected in 2026.

auto_awesomeAnalysis

This filing provides the full financial results for Q4 and full year 2025, building on the preliminary revenue announced in January. The company reported significant revenue growth and a positive shift to GAAP net income in Q4 2025. Most notably, BioLife Solutions introduced 2026 guidance that includes an expectation of full-year GAAP profitability, a key milestone following its strategic divestitures to become a focused cell processing company. This outlook, coupled with strong adjusted EBITDA expansion, signals improved operational efficiency and a positive trajectory for the company's financial health.